Altamira Therapeutics Statistics
Total Valuation
CYTOF has a market cap or net worth of 342,928. The enterprise value is 1.13 million.
| Market Cap | 342,928 |
| Enterprise Value | 1.13M |
Important Dates
The last earnings date was Thursday, September 18, 2025.
| Earnings Date | Sep 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CYTOF has 5.72 million shares outstanding. The number of shares has increased by 351.86% in one year.
| Current Share Class | 5.72M |
| Shares Outstanding | 5.72M |
| Shares Change (YoY) | +351.86% |
| Shares Change (QoQ) | +39.21% |
| Owned by Insiders (%) | 19.66% |
| Owned by Institutions (%) | 0.00% |
| Float | 4.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.08 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.20 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.26 |
Financial Position
The company has a current ratio of 0.11, with a Debt / Equity ratio of 0.19.
| Current Ratio | 0.11 |
| Quick Ratio | 0.09 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.18 |
| Interest Coverage | -109.87 |
Financial Efficiency
Return on equity (ROE) is -108.79% and return on invested capital (ROIC) is -59.89%.
| Return on Equity (ROE) | -108.79% |
| Return on Assets (ROA) | -45.75% |
| Return on Invested Capital (ROIC) | -59.89% |
| Return on Capital Employed (ROCE) | -115.39% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -513,903 |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 2.75 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 48.21 |
| Average Volume (20 Days) | 5,486 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.89 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.56M |
| Pretax Income | -5.65M |
| Net Income | -5.65M |
| EBITDA | n/a |
| EBIT | -5.56M |
| Earnings Per Share (EPS) | -1.31 |
Balance Sheet
The company has 3,755 in cash and 790,049 in debt, giving a net cash position of -786,294 or -0.14 per share.
| Cash & Cash Equivalents | 3,755 |
| Total Debt | 790,049 |
| Net Cash | -786,294 |
| Net Cash Per Share | -0.14 |
| Equity (Book Value) | 4.07M |
| Book Value Per Share | 0.71 |
| Working Capital | -2.06M |
Cash Flow
In the last 12 months, operating cash flow was -4.29 million and capital expenditures -103,087, giving a free cash flow of -4.40 million.
| Operating Cash Flow | -4.29M |
| Capital Expenditures | -103,087 |
| Free Cash Flow | -4.40M |
| FCF Per Share | -0.77 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CYTOF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -351.86% |
| Shareholder Yield | n/a |
| Earnings Yield | -1,648.43% |
| FCF Yield | -1,282.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 13, 2023. It was a reverse split with a ratio of 0.05.
| Last Split Date | Dec 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |